A5083965217- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Reproductive System and Pregnancy
- Immune Cell Function and Interaction
- Colorectal Cancer Screening and Detection
- PARP inhibition in cancer therapy
- Gut microbiota and health
- Cancer survivorship and care
- Dietary Effects on Health
- Cancer-related molecular mechanisms research
- Beetle Biology and Toxicology Studies
- DNA Repair Mechanisms
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
KU Leuven
2019-2024
Resistance to platinum-based chemotherapy represents a major clinical challenge for many tumors, including epithelial ovarian cancer. Patients often experience several response-relapse events, until tumors become resistant and life expectancy drops 12-15 months. Despite improved knowledge of the molecular determinants platinum resistance, lack applicability limits exploitation potential targets, leaving patients with limited options. Serine biosynthesis has been linked cancer growth poor...
A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients received an immunomodulatory five-drug cocktail (IDC) consisting low-dose cyclophosphamide, aspirin, lansoprazole, vitamin D, and curcumin starting 2 weeks before radioimmunotherapy. Pembrolizumab was administered three-weekly from day 15 onwards; one the tumor lesions irradiated (8Gyx3) on days 15, 17, 19. The primary endpoint objective response rate...
Uterine leiomyosarcomas (uLMS) are aggressive tumours with poor prognosis and limited treatment options. Although immune checkpoint blockade (ICB) has proven effective in some 'challenging-to-treat' cancers, clinical trials showed that uLMS do not respond to ICB. Emerging evidence suggests aberrant PI3K/mTOR signalling can drive resistance We therefore explored the relevance of pathway for ICB pharmacological inhibition this sensitise these
<h3>Introduction/Background</h3> To decrease immunosuppression and enhance T-cell activation in the tumour microenvironment, we conducted an open-label, investigator-initiated, multicohort, phase II trial (NCT03192059) of pembrolizumab with multimodal immunomodulation. <h3>Methodology</h3> Chemotherapy-pretreated patients were recruited into two experimental cohorts (cervical carcinoma or endometrial carcinoma) one exploratory cohort (uterine sarcoma). Patients received immunomodulatory...